|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
AMI is associated with polymorphisms in the NOS3 and FGB but not in PAI-1 genes in young adults.
|
17126309 |
2007 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Multivariable logistic regression analyses and stepwise forward selection procedures revealed that seven different polymorphisms were significantly (P<0.005) associated with MI in individuals with low or high serum concentrations of HDL- or LDL-cholesterol or of TG: the 190T --> C (Trp64Arg) polymorphism of ADRB3 in individuals with low HDL-cholesterol; the 1018C --> T (Thr145Met) polymorphism of GP1BA, the A --> G (Ile646Val) polymorphism of AKAP10, and the -55C --> T polymorphism of UCP3 in individuals with high HDL-cholesterol; the -603A --> G polymorphism of F3 and the -11377C --> G polymorphism of ADIPOQ in individuals with low LDL-cholesterol; the 1018C --> T polymorphism of GP1BA in individuals with low TG; and the 4G --> 5G polymorphism of PAI1 in individuals with high TG.
|
17786291 |
2007 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
PAI-1 4G/4G genotype was the only independent variable (OR 2.67, 95%CI 1.43-4.96, P = 0.002) associated with MI in this regression model.
|
17721742 |
2008 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
Recent large Japanese case-control studies identified connexin-37 (GJA-4), plasminogen activator inhibitor-1 (PAI-1), and stromelysin-1 (MMP-3) polymorphisms as risk factors for MI, but the prevalence of these genotypes among different racial groups in the U.S. needs to be determined.
|
15234427 |
2004 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
SERPINE1 haplotypes are mildly associated with plasma levels of PAI-1 and with the risk of MI in nonsmokers.
|
17656673 |
2007 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
PAI-1 4G/4G genotype was the only independent variable (OR 2.67, 95%CI 1.43-4.96, P = 0.002) associated with MI in this regression model.
|
17721742 |
2008 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.
|
10577569 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) has already been associated with atherosclerosis; myocardial infarction; and cardiovascular disease risk factors such as obesity, insulin resistance, and dyslipidemia.
|
20127289 |
2010 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Recent large Japanese case-control studies identified connexin-37 (GJA-4), plasminogen activator inhibitor-1 (PAI-1), and stromelysin-1 (MMP-3) polymorphisms as risk factors for MI, but the prevalence of these genotypes among different racial groups in the U.S. needs to be determined.
|
15234427 |
2004 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We assessed the 4G/5G polymorphism of the PAI-I gene in 500 subjects including 148 normal controls, 23 subjects with normal coronary arteries, 28 subjects with a paradoxical acetylcholine response, 97 subjects with angina pectoris (AP) and 204 subjects with myocardial infarction (MI).
|
9544737 |
1998 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that PAI-1 promoter polymorphism influences the development of myocardial infarction through its effect on thrombus formation in patients with preexisting coronary atheroma.
|
9012634 |
1997 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The PAI-1 4G/5G genotype was not associated with risk of myocardial infarction or other cardiovascular mortality.
|
10618306 |
2000 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The Mendelian randomization meta-analysis confirmed previous knowledge that the PAI-1 4G allele slightly increases the risk for MI.
|
24695040 |
2014 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The 4G allele is associated with higher PAI-1 levels, but this study does not support an association of the PAI gene polymorphisms with the risk of either myocardial infarction or stroke.
|
17161063 |
2006 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In a multiple logistic regression analysis, age (OR 1.02 [95%-CI: 1.00-1.05]), total cholesterol (OR 1.40 [95%-CI: 1.14-1.71]), C-reactive protein levels >0.33 mg/l (OR: 1.87 [95%-CI: 1.10-3.20]), plasminogen activator inhibitor-1 4G/4G (OR: 1.84 [95%-CI: 1.27-2.66]), and MTHFR TT genotype (OR 1.62 [95%-CI: 1.08-2.42]), were all associated with a family history of myocardial infarction.
|
10456448 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in plasminogen activator inhibitor-1 (PAI-1, SERPINE1) and tissue plasminogen activator (tPA, PLAT), such as PAI-1 (-675 4G/5G deletion/insertion) and tPA (Alu insertion/deletion [I/D]), are associated with strokes, myocardial infarctions, bacterial infections and septic shock severity, and trauma.
|
23570848 |
2013 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
05), total cholesterol (OR 1.35, 95% CI 1.11 to 1.65), plasminogen activator inhibitor-1 4G/4G (OR 1.72, 95% CI 1.20 to 2.45), and CRP levels >0.33 mg/L (OR 1.75, 95% CI 1.05 to 2.91) were all independently associated with a positive family history of myocardial infarction.
|
10634818 |
2000 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Increased plasma levels of coagulation proteins such as fibrinogen and plasminogen activator inhibitor-1 (PAI-1) are associated with an increased risk of myocardial infarction.
|
10554707 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Two are associated with thrombophilia (765 4G/5G and -844 A>G, in the promoter), risk of myocardial infarction and postoperative deep venous thrombosis related to higher than normal levels of PAI-1.
|
21663586 |
2011 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
To examine interactions among the angiotensin converting enzyme (ACE) insertion/deletion, plasminogen activator inhibitor-1 (PAI-1) 4G/5G, and tissue plasminogen activator (t-PA) insertion/deletion gene polymorphisms on risk of myocardial infarction using data from 343 matched case-control pairs from the Physicians Health Study.
|
15119966 |
2004 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
MTHFRA1298C and PAI-1 deletions were most frequent genetic variants in risk groups for MI in patients with diabetes mellitus (value of odds ratio sequentially [OR] = 3.79, p = 0.06 and [OR] = 5 × 10(8), p = 0.000).
|
22752805 |
2012 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
SERPINE1 haplotypes are mildly associated with plasma levels of PAI-1 and with the risk of MI in nonsmokers.
|
17656673 |
2007 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly.
|
10928474 |
2000 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The insertion/deletion polymorphism (4G/5G) in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene has been associated with an increased risk of myocardial infarction.
|
10971410 |
2000 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In our study, the FXIII 34Leu allele was associated with a lower risk of MI (P = 0.009), however, the PAI-1 4G allele showed no interaction with this polymorphism.
|
10030380 |
1999 |